Sage Therapeutics Unanimously Rejects Biogen’s Takeover Offer, Initiates Strategic Alternatives Exploration

Sage Therapeutics announced on Monday that its board of directors has unanimously rejected the takeover offer from Biogen. The decision comes as the company embarks on a new path, exploring strategic alternatives to enhance shareholder value. This move signifies Sage’s commitment to evaluating all options to ensure the best future for its stakeholders. The company’s stock saw a notable increase following the announcement, reflecting investor interest in the potential outcomes of this strategic shift. As Sage navigates this new direction, the market watches closely, anticipating the next steps in this evolving corporate narrative.